Health Care [ 5/12 ] | Biotechnology [ 25/74 ]
NASDAQ | Common Stock
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.
Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial.
Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, TheU. S.
Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the University of Pennsylvania, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the Walter Reed Army Institute of Research, and The Wistar Institute.
The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 4, 25 | -0.60 Increased by +46.43% | -0.83 Increased by +27.88% |
| Nov 7, 24 | -0.89 Decreased by -584.62% | -1.15 Increased by +22.61% |
| Aug 8, 24 | -1.19 Decreased by -815.38% | -1.10 Decreased by -8.18% |
| May 13, 24 | -1.31 Decreased by -718.75% | -1.00 Decreased by -31.00% |
| Mar 6, 24 | -1.12 Decreased by -433.33% | -1.27 Increased by +11.81% |
| Nov 9, 23 | -0.13 Increased by +13.33% | -0.13 |
| Aug 9, 23 | -0.13 Increased by +71.74% | -0.14 Increased by +7.14% |
| May 10, 23 | -0.16 Increased by +55.56% | -0.14 Decreased by -14.29% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 116.99 K Increased by +13.97% | -19.38 M Increased by +22.48% | Decreased by -16.57 K% Increased by +31.99% |
| Sep 30, 24 | 0.00 Decreased by -100.00% | -25.17 B Decreased by -74.07 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 100.76 K Decreased by -55.41% | -32.24 M Increased by +9.28% | Decreased by -31.99 K% Decreased by -103.45% |
| Mar 31, 24 | 0.00 Decreased by -100.00% | -30.47 M Decreased by -101.03% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 102.65 K Decreased by -17.66% | -25.00 M Increased by +51.61% | Decreased by -24.36 K% Increased by +41.23% |
| Sep 30, 23 | 388.45 K Decreased by -95.76% | -33.93 M Increased by +14.36% | Decreased by -8.73 K% Decreased by -1.92 K% |
| Jun 30, 23 | 225.97 K Decreased by -71.19% | -35.53 M Increased by +68.40% | Decreased by -15.73 K% Decreased by -9.68% |
| Mar 31, 23 | 114.94 K Decreased by -42.26% | 2.95 B Increased by +3.61 K% | Increased by +2.57 M% Increased by +6.19 K% |